Tibet AIM Pharm Past Earnings Performance
Past criteria checks 2/6
Tibet AIM Pharm has been growing earnings at an average annual rate of 4.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 9.4% per year. Tibet AIM Pharm's return on equity is 4.7%, and it has net margins of 5.3%.
Key information
4.9%
Earnings growth rate
4.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 9.4% |
| Return on equity | 4.7% |
| Net Margin | 5.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Tibet AIM Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 656 | 35 | 323 | 13 |
| 31 Dec 23 | 667 | 15 | 298 | 14 |
| 30 Sep 23 | 803 | 47 | 327 | 22 |
| 30 Jun 23 | 847 | 46 | 316 | 17 |
| 31 Mar 23 | 842 | 44 | 320 | 13 |
| 31 Dec 22 | 857 | 44 | 325 | 13 |
| 30 Sep 22 | 799 | 47 | 288 | 8 |
| 30 Jun 22 | 772 | 44 | 268 | 9 |
| 31 Mar 22 | 754 | 46 | 240 | 7 |
| 01 Jan 22 | 725 | 42 | 217 | 11 |
| 30 Sep 21 | 717 | 41 | 202 | 11 |
| 30 Jun 21 | 693 | 38 | 201 | 11 |
| 31 Mar 21 | 665 | 40 | 197 | 11 |
| 31 Dec 20 | 603 | 41 | 178 | 7 |
| 30 Sep 20 | 609 | 39 | 176 | 5 |
| 30 Jun 20 | 573 | 39 | 165 | 5 |
| 31 Mar 20 | 543 | 37 | 150 | 5 |
| 31 Dec 19 | 553 | 37 | 147 | 5 |
| 30 Sep 19 | 500 | 30 | 52 | 16 |
| 30 Jun 19 | 502 | 22 | 64 | 14 |
| 31 Mar 19 | 504 | 26 | 105 | 14 |
| 31 Dec 18 | 489 | 25 | 133 | 16 |
| 30 Sep 18 | 451 | 38 | 245 | 4 |
| 30 Jun 18 | 408 | 55 | 232 | 7 |
| 31 Mar 18 | 393 | 61 | 221 | 7 |
| 31 Dec 17 | 380 | 60 | 217 | 4 |
| 30 Sep 17 | 406 | 53 | 237 | 2 |
| 30 Jun 17 | 441 | 52 | 262 | 0 |
| 31 Mar 17 | 476 | 56 | 279 | 0 |
| 31 Dec 16 | 452 | 55 | 259 | 0 |
| 31 Dec 15 | 347 | 50 | 190 | 0 |
| 31 Dec 14 | 291 | 32 | 152 | 0 |
| 31 Dec 13 | 221 | 20 | 115 | 0 |
Quality Earnings: 002826 has a large one-off loss of CN¥19.9M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 002826's current net profit margins (5.3%) are higher than last year (5.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002826's earnings have grown by 4.9% per year over the past 5 years.
Accelerating Growth: 002826's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002826 had negative earnings growth (-20.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 002826's Return on Equity (4.7%) is considered low.